Clermont Pharmaceuticals, a privately held company in Tampa, Florida, has announced that its investigational candidate, non-preserved latanoprost, achieved the primary endpoint of non-inferiority to Xalatan (Pfizer's latanoprost ophthalmic solution 0.005%) in a Phase III study in patients diagnosed with open-angle glaucoma, and that it will be seeking a potential US marketing partner "in the near future".
In addition to demonstrating non-inferiority, non-preserved latanoprost was better tolerated than Xalatan, with statistically fewer ocular symptoms on instillation and significantly fewer subjects with conjunctival hyperaemia, Clermont said. Based on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?